Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517502-28-01

Acronym

NL80854.018.22

Enrollment

Registered

2025-01-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Brief summary

cost-effectiveness of therapeutic drug monitoring based drug de-escalation

Interventions

DRUGEntyvio 108 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
cost-effectiveness of therapeutic drug monitoring based drug de-escalation	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026